Probiotic Mediation of Immune Suppressor Dosage in Autoimmune Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Chronic autoimmune diseases such as autoimmune hemolytic anemia, inflammatory bowel disease, and atopic dermatitis in humans and animals require long-term treatment with anti-inflammatory drugs and immune suppressors, which often lead to severe side effects, making it challenging to reduce or eliminate these drugs without symptom recurrence.
Innovation Solution
Administration of probiotics Pediococcus acidilactici and Saccharomyces boulardii, either alone or in combination with steroids and immune suppressors, to reduce the dosage and side effects of conventional treatments for autoimmune hemolytic anemia, inflammatory bowel disease, and atopic dermatitis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If long-term treatment with steroids and immune suppressors is used, then chronic autoimmune diseases are controlled, but severe side effects occur
Solution Approach 1:
The patent introduces probiotics as an intermediary substance that modulates the immune system. The probiotics act as a mediator between the host and the autoimmune response, enabling disease control while reducing dependence on conventional drugs with severe side effects. The probiotic strains (such as Lactobacillus and Bifidobacterium) modulate immune function through specific mechanisms including cytokine production and immune cell regulation.
Solution Approach 2:
The patent changes the parameter of immune system modulation by switching from direct immunosuppression (steroids/immune suppressors) to probiotic-based immunomodulation. This parameter change allows for disease control through a different mechanism that avoids the severe side effects of conventional drugs while maintaining therapeutic efficacy.
2Object-affected harmful factors
If drug dosages are reduced to minimize side effects, then patient safety improves, but symptom recurrence occurs
Solution Approach 1:
The patent applies preliminary action by introducing probiotics before reducing or eliminating conventional drugs. The probiotics are administered concurrently with or before dose reduction to prepare the immune system for the transition, ensuring that symptom control is maintained during the tapering process and preventing recurrence upon drug cessation.
Solution Approach 2:
The patent implements feedback mechanisms through monitoring of disease symptoms and immune parameters during probiotic treatment. This feedback allows for adjustment of probiotic dosage and timing to ensure sustained symptom control while minimizing drug requirements, creating a dynamic adaptation that prevents symptom recurrence.
3Object-affected harmful factors
If conventional drugs are eliminated entirely, then side effects are eliminated, but disease remission is difficult to achieve
Solution Approach 1:
The patent uses probiotics as an intermediary that bridges the gap between drug therapy and complete drug elimination. The probiotics maintain sufficient immune modulation to achieve remission without requiring continuous conventional drug administration, enabling safe elimination of drugs while maintaining disease control through the probiotic-mediated immune system.
Data Source
AI summary
This invention relates to use of probiotics, particularly P acidilactici and S boulardii, for use in conjunction with steroids and other immune suppressor agents to ameliorate symptoms of autoimmune diseases, especially disease symptoms arising from the body's production of antibodies against autologous blood cells. The practice of the invention sustains ameliorative response associated with immune suppressor agents while lowering the amount of immune suppressor agents required for treatment.